Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
- PMID: 9207639
- DOI: 10.1016/s0735-1097(97)00118-6
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
Abstract
Objectives: This study was undertaken to define and better understand the characteristics and outcomes of patients with diabetes treated for acute myocardial infarction with contemporary thrombolysis.
Background: Although thrombolysis has substantially improved survival of patients with myocardial infarction, diabetes mellitus remains an independent predictor for a poor prognosis.
Methods: We characterized the contemporary relation between diabetes and outcome after myocardial infarction treated with thrombolytic agents from a large international cohort. Of 41,021 patients randomized to receive accelerated tissue-type plasminogen activator (t-PA), streptokinase or a combination of both agents in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries study, there were 5,944 patients with diabetes and 34,888 patients without diabetes.
Results: Patients with diabetes were older and more likely to be female, to present with anterior wall infarction, to receive thrombolysis later and to have triple-vessel coronary artery disease. Mortality at 30 days was highest among diabetic patients treated with insulin (12.5%) compared with non-insulin-treated diabetic (9.7%) and nondiabetic (6.2%) patients (p < 0.001). Mortality was lowest among those with diabetes receiving accelerated t-PA, which is consistent with the results of the overall patient cohort. Although stroke occurred more frequently among diabetic (1.9%) than nondiabetic patients (1.4%, p < 0.001), there was no significant difference in the rates of intracranial hemorrhage. Cardiac failure, shock, atrioventricular block and atrial flutter/ fibrillation were more common among diabetic patients. The proportion of patients undergoing revascularization was similar between patients with and without diabetes, although diabetic patients were more likely to undergo coronary artery bypass graft surgery (10.4% vs. 8.3%). Diabetes remained an independent predictor for mortality at 1-year follow-up (14.5% vs. 8.9%, p < 0.001).
Conclusions: Diabetes, alone and in association with its comorbidities, portends a substantially worse 30-day and 1-year prognosis for patients with myocardial infarction.
Similar articles
-
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.JAMA. 1996 Mar 13;275(10):777-82. JAMA. 1996. PMID: 8598594 Clinical Trial.
-
Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.Am J Cardiol. 1996 Dec 15;78(12):1338-44. doi: 10.1016/s0002-9149(96)00654-6. Am J Cardiol. 1996. PMID: 8970403
-
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.J Am Coll Cardiol. 1997 Feb;29(2):240-9. doi: 10.1016/s0735-1097(96)00492-5. J Am Coll Cardiol. 1997. PMID: 9014973 Clinical Trial.
-
Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.J Am Coll Cardiol. 1995 Jun;25(7 Suppl):10S-17S. doi: 10.1016/0735-1097(95)00188-a. J Am Coll Cardiol. 1995. PMID: 7775708 Review.
-
Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.Pharmacoeconomics. 1995 Nov;8(5):428-59. doi: 10.2165/00019053-199508050-00006. Pharmacoeconomics. 1995. PMID: 10172669 Review.
Cited by
-
Diabetes is an independent predictor of survival 17 years after myocardial infarction: follow-up of the TRACE registry.Cardiovasc Diabetol. 2010 Jun 2;9:22. doi: 10.1186/1475-2840-9-22. Cardiovasc Diabetol. 2010. PMID: 20525192 Free PMC article.
-
Albumin excretion in diabetic patients in the setting of acute myocardial infarction: association with 3-year mortality.Diabetologia. 2004 Sep;47(9):1511-8. doi: 10.1007/s00125-004-1486-4. Epub 2004 Aug 18. Diabetologia. 2004. PMID: 15322753
-
Percutaneous coronary intervention in diabetics.Rev Endocr Metab Disord. 2004 Aug;5(3):277-85. doi: 10.1023/B:REMD.0000032417.33194.09. Rev Endocr Metab Disord. 2004. PMID: 15211100 Review. No abstract available.
-
Update on the use of trandolapril in the management of cardiovascular disorders.Vasc Health Risk Manag. 2008;4(6):1147-58. doi: 10.2147/vhrm.s3467. Vasc Health Risk Manag. 2008. PMID: 19337528 Free PMC article. Review.
-
Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study.Cardiovasc Diabetol. 2023 May 22;22(1):121. doi: 10.1186/s12933-023-01857-w. Cardiovasc Diabetol. 2023. PMID: 37217967 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical